Cancer Research UK on Google+ Cancer Research UK on Facebook Cancer Research UK on Twitter
Skip navigation

A trial of hydroxychloroquine with imatinib for chronic myeloid leukaemia (CHOICES)

This trial is looking at adding a drug called hydroxychloroquine to treatment for chronic myeloid leukaemia (CML) that has already responded well to imatinib.

Doctors often treat CML with a type of biological therapy called imatinib (also known as Glivec). Many people respond well to imatinib. But even if you have a very good response, there may be a small number of leukaemia cells left in your body. This is called residual disease. Doctors can see if there is any residual disease using a test called polymerase chain reaction (PCR) which looks for genetic changes in cells.

The people taking part in this trial have had a good response to imatinib, but their doctors can see there are still some cancer cells by doing a PCR test. Everybody taking part will carry on having imatinib, but some people will also start taking a drug called hydroxychloroquine.

Hydroxychloroquine is already used to treat other diseases such as rheumatoid arthritis. Doctors think it may also help to get rid of residual disease in chronic myeloid leukaemia.

The aims of the trial are to

  • See if imatinib with hydroxychloroquine is better at reducing the number of residual leukaemia cells than imatinib alone
  • Learn more about the side effects

Recruitment

Start 01/04/2010
End 30/09/2014

Phase

Phase 2

Who can enter

You can enter this trial if you

  • Were diagnosed with chronic myeloid leukaemia in chronic phase and have been taking imatinib for at least 1 year and are on a stable dose
  • Have had a good response to imatinib (this is called a major cytogenetic response and your doctor can confirm this for you)
  • Have leukaemia cells with a genetic change that doctors can monitor using a PCR test
  • Have been taking the same dose of imatinib for at least 6 months
  • Have satisfactory blood test results
  • Are well enough to be up and about for at least half the day (performance status 0, 1 or 2)
  • Are willing to use reliable contraception during the trial and for 3 months afterwards if there is any chance you or your partner could become pregnant
  • Are at least 18 years old

You cannot enter this trial if you

  • Are currently having radiotherapy or any other cancer treatment
  • Have had major surgery, chemotherapy or an experimental drug in the last 4 weeks (or have not recovered from side effects of earlier treatment)
  • Have an eye condition called maculopathy
  • Have high blood pressure that cannot be controlled with medication
  • Have heart failure, another heart problem that is a cause for concern, or any other serious medical condition (the trial doctors can advise you about this)
  • Are pregnant or breastfeeding

Trial design

This is a randomised trial. The people taking part are put into 1 of 2 treatment groups by a computer. Neither you nor your doctor will be able to decide which group you are in.

Half the people taking part will just carry on taking imatinib. The other half will carry on taking imatinib, but will also have hydroxychloroquine. They take it as a tablet twice a day, for up to a year.

The researchers will take extra blood samples from some people taking part to learn more about what happens to both drugs in the body. This is called pharmacokinetics. They will also ask 10 people in each group to have 2 extra bone marrow tests. This is to see if having both drugs together works better than having imatinib alone.

Hospital visits

You will see the doctors and have some tests at the beginning of the trial. The tests include

People taking hydroxychloroquine will have another ECG after 6 weeks of treatment, and they have regular eye tests during the trial.

Everybody taking part goes to see the trial team weekly for the first 4 weeks, every 2 weeks for the next 4 weeks, and then once every 4 weeks for nearly a year. After a year, you have follow up appointments every 3 months for the next 12 months.

Side effects

The possible side effects of hydroxychloroquine include

Very rarely, if you take hydroxychloroquine for a long period of time, it can affect your eyesight. So, people taking it in this trial have regular eye tests.

There is more information about possible side effects of imatinib on CancerHelp UK. There may be some side effects caused by having both drugs at the same time that doctors don’t know about yet.

Location of trial

  • Cambridge
  • Glasgow
  • Liverpool
  • London
  • Nottingham

For more information

Please note: we cannot help you to join a specific trial. Unless we state otherwise in this trial summary, you need to print this page and take it to your own doctor to discuss.

Find out how to join a trial or contact our cancer information nurses for other questions about cancer by phone (0808 800 4040), by email, or at

The Information Nurses
Cancer Research UK
Angel Building
407 St John Street
London
EC1V 4AD

Chief Investigator

Professor Tessa Holyoake

Supported by

Cancer Research UK Clinical Trials Unit, Glasgow
Experimental Cancer Medicine Centre (ECMC)
Medical Research Council (MRC)
NIHR Clinical Research Network: Cancer
Rate this page:
Submit rating
Rate this page
Rate this page for no comments box
Please enter feedback to continue submitting
Send feedback
Question about cancer? Contact our information nurse team

No Error

Updated: 12 March 2014